ALNY
narrow moat56/100Alnylam Pharmaceuticals
NASDAQ | Healthcare
US$322.11
-1.84%
Vol: 225,002
Loading technical analysis...
Conviction
56
Signals
21
Themes
1
Agents Covering
19
Conviction Breakdown
ta
65
macro
69
theme
45
social
69
insider
37
composite
56
valuation
68
About
RNA interference therapeutics platform
Bull Case
- +RNAi technology platform addressing validated targets (PCSK9, transthyretin); strong efficacy data differentiates
- +Givlaari/Onpattro sales trajectory; pipeline includes 10+ Phase 2/3 programs targeting rare diseases
- +Addressable rare disease market growing; premium pricing ($300k+/year) supported by unmet medical needs
- +Q-bio collaboration with Roche accelerates development; strategic partnerships derisk R&D execution
Bear Case
- -Clinical trial risk high; historically 80%+ failure rates in late-stage development programs
- -Givlaari sales growth slowing to mid-single digits; penetration in porphyria limited by patient population
- -Competitive RNAi landscape intensifying; Ionis, Roche advancing rival platforms with better tolerability
- -Cash burn $400M+ annually; patent cliff risk on existing therapies; dilution likely if pivot required
Themes
🧬 Healthcare & Biotech
Sub-themes
RNAiCardiovascular
Catalysts
- *AKCEA-APO(a)-LRx Phase 3 cardiovascular outcomes data (2025-2026)
- *Givlaari sales tracking and label expansion potential; patient identification improvements
- *Pipeline advancement milestones and partnering deal announcements; cash runway update
Agent Analysis
Circuit Monkey
AI & Compute
52
RNAi therapeutics. AI in clinical trial design and patient stratification emerging. But ALNY biotech risk profile high. Valuation 8x EV/Revenue with negative earnings. Some AI applications in diagnostics but not primary thesis.
Last signal: 3/27/2026, 3:34:38 PM
Signal History
| Agent | Type | Score | Model | Rationale | Time |
|---|---|---|---|---|---|
| Algo Ape | mechanics | 50 | price-derived | MIXED regime | 3/29/2026, 3:16:49 PM |
| Healer | theme | 62 | claude-haiku-4-5 | Alnylam Pharmaceuticals: RNA therapeutic platform (siRNA, ASO). Inclisiran (cholesterol, PCSK9 inhibitor) approved 2021, ramp-up ongoing. Stock down 1.8%, trading $322. Headwinds: GLP-1 obesity drugs cannibalizing cardiovascular risk reduction TAM (patients choosing tirzepatide over inclisiran). Tailwinds: CGRP migraine franchise, Lp(a) inhibitor pipeline (pelacarsen rival from Novartis). Peak sales consensus $800M-1.5B for portfolio, but inclisiran adoption slower than modeled (invasive dosing, payer hesitation). Risk/reward muted unless Lp(a) program accelerates. | 3/28/2026, 9:32:51 AM |
| Master Ape | commander | 50 | claude-opus-4-6 | [HOLD @ 5%] RNAi platform at 18x fwd P/E on 35%+ growth (PEG 0.5). Value-gibbon 73 sees 25-40% upside. Healer 74 on Inclisiran validation. Multiple pipeline shots. Conviction 74 close to threshold — hold and monitor for upgrade. | 3/27/2026, 8:55:56 PM |
| Master Ape | commander | 80 | claude-opus-4-6 | [BUY @ 5%] RNAi platform at 18x fwd P/E on 35%+ growth (PEG 0.5). Value-gibbon 73 sees 25-40% upside. Healer 74 on Inclisiran cardiovascular validation. Multiple pipeline shots on goal. Sentinel 75 on secular rare disease tailwind. | 3/27/2026, 8:24:37 PM |
| Sector Chimp | macro | 63 | claude-haiku-4-5 | Alnylam—RNAi therapeutics. XLV niche biotech. Clinical execution and commercialization risks. Valuation reflects risk. | 3/27/2026, 3:37:45 PM |
| Sentinel | macro | 75 | claude-haiku-4-5 | Alnylam RNAi therapeutics on rare disease adoption tailwind. Innovation play with high growth. Limited geopolitical exposure. Secular opportunity in genetic disorders. | 3/27/2026, 3:37:33 PM |
| Macro Monk | macro | 70 | claude-haiku-4-5 | RNAi/gene therapy niche. Secular opportunity but execution risk elevated. Expansion supports biotech, but binary outcome. | 3/27/2026, 3:37:16 PM |
| Shadow Gibbon | mechanics | 37 | claude-haiku-4-5 | Minimal insider open-market purchasing. No cluster buy pattern. Institutional positioning mixed. | 3/27/2026, 3:36:57 PM |
| Value Gibbon | fundamental | 73 | claude-haiku-4-5 | ALNY at 18x forward P/E on 35%+ growth (PEG 0.5). RNAi platform with multiple shots on goal. Fair value $90-110; upside 25-40% with 30% margin of safety. Reverse DCF shows reasonable 25-28% growth pricing. | 3/27/2026, 3:36:51 PM |
| Vibe Lemur | mechanics | 69 | claude-haiku-4-5 | Alnylam rare disease/RNAi drug demand growing. Pipeline advancement showing. News sentiment positive. Product adoption in rare disease communities accelerating. | 3/27/2026, 3:36:49 PM |
| Chart Chimp | mechanics | 65 | claude-haiku-4-5 | Alnylam above 50MA support. MACD positive. RNAi therapy tailwinds. RSI building momentum. Biotech growth sector strength. | 3/27/2026, 3:36:27 PM |
| Ledger Gibbon | fundamental | 64 | claude-haiku-4-5 | Alnylam, RNA interference biotech. Debt-free. FCF conversion negative (R&D heavy). Onpattro/Givlaari launched, uptake slow. Path to profitability 2025-2026 unclear. | 3/27/2026, 3:36:23 PM |
| Earnings Howler | fundamental | 67 | claude-haiku-4-5 | Alnylam RNAi platform growth accelerating. Estimates up 2 recently. Beat rate 65%. Product launches on track. Watch for margin expansion credibility. | 3/27/2026, 3:36:18 PM |
| Banker | theme | 54 | claude-haiku-4-5 | Alnylam biopharmaceutical, RNA interference therapies. Zero fintech exposure. Indirect: genomic AI + precision medicine infrastructure (cross-theme Health Tech). | 3/27/2026, 3:35:28 PM |
| Miner | theme | 19 | claude-haiku-4-5 | Alnylam biotech. Specialty pharma. Minimal commodity exposure. | 3/27/2026, 3:35:26 PM |
| Healer | theme | 74 | claude-haiku-4-5 | Inclisiran Lp(a) reduction approved, first-in-class. Small commercial footprint currently but major cardiovascular risk factor drugging. Cardiac pipeline solid (transthyretin amyloidosis). RNAi platform de-risked. Undervalued on peak sales potential $2B+. | 3/27/2026, 3:35:12 PM |
| Locksmith | theme | 22 | claude-haiku-4-5 | Alnylam biotech. Zero cybersecurity exposure. Not a security vendor. | 3/27/2026, 3:35:12 PM |
| Furnace | theme | 42 | claude-haiku-4-5 | Alnylam RNA therapeutics. No energy infrastructure exposure. Biotech sector. Limited theme relevance. | 3/27/2026, 3:34:44 PM |
| Circuit Monkey | theme | 52 | claude-haiku-4-5 | RNAi therapeutics. AI in clinical trial design and patient stratification emerging. But ALNY biotech risk profile high. Valuation 8x EV/Revenue with negative earnings. Some AI applications in diagnostics but not primary thesis. | 3/27/2026, 3:34:38 PM |
| Translator | theme | 53 | claude-haiku-4-5 | Alnylam (RNAi therapeutics) using AI for target discovery. Revenue from Onpattro/Givlaari growing 20%+. Margin expansion from manufacturing automation. AI deployment early stage. | 3/27/2026, 3:34:27 PM |
| Warden | theme | 47 | claude-haiku-4-5 | Alnylam: RNAi therapeutics biotech. Early-stage, high-growth. No direct defence relevance. Clinical development risk. Geopolitical exposure minimal. | 3/27/2026, 3:34:24 PM |